QQQ   359.69 (+0.40%)
AAPL   173.09 (+1.10%)
MSFT   318.88 (+0.99%)
META   304.51 (+1.43%)
GOOGL   133.08 (+1.70%)
AMZN   128.93 (+1.42%)
TSLA   248.80 (-0.57%)
NVDA   444.74 (+2.24%)
NIO   8.77 (-2.99%)
BABA   86.16 (-0.67%)
AMD   102.24 (-0.56%)
T   14.75 (-1.80%)
F   12.27 (-1.21%)
MU   67.44 (-0.87%)
CGC   0.73 (-7.37%)
GE   108.65 (-1.72%)
DIS   81.41 (+0.44%)
AMC   8.05 (+0.75%)
PFE   33.76 (+1.78%)
PYPL   58.58 (+0.21%)
NFLX   380.13 (+0.67%)
QQQ   359.69 (+0.40%)
AAPL   173.09 (+1.10%)
MSFT   318.88 (+0.99%)
META   304.51 (+1.43%)
GOOGL   133.08 (+1.70%)
AMZN   128.93 (+1.42%)
TSLA   248.80 (-0.57%)
NVDA   444.74 (+2.24%)
NIO   8.77 (-2.99%)
BABA   86.16 (-0.67%)
AMD   102.24 (-0.56%)
T   14.75 (-1.80%)
F   12.27 (-1.21%)
MU   67.44 (-0.87%)
CGC   0.73 (-7.37%)
GE   108.65 (-1.72%)
DIS   81.41 (+0.44%)
AMC   8.05 (+0.75%)
PFE   33.76 (+1.78%)
PYPL   58.58 (+0.21%)
NFLX   380.13 (+0.67%)
QQQ   359.69 (+0.40%)
AAPL   173.09 (+1.10%)
MSFT   318.88 (+0.99%)
META   304.51 (+1.43%)
GOOGL   133.08 (+1.70%)
AMZN   128.93 (+1.42%)
TSLA   248.80 (-0.57%)
NVDA   444.74 (+2.24%)
NIO   8.77 (-2.99%)
BABA   86.16 (-0.67%)
AMD   102.24 (-0.56%)
T   14.75 (-1.80%)
F   12.27 (-1.21%)
MU   67.44 (-0.87%)
CGC   0.73 (-7.37%)
GE   108.65 (-1.72%)
DIS   81.41 (+0.44%)
AMC   8.05 (+0.75%)
PFE   33.76 (+1.78%)
PYPL   58.58 (+0.21%)
NFLX   380.13 (+0.67%)
QQQ   359.69 (+0.40%)
AAPL   173.09 (+1.10%)
MSFT   318.88 (+0.99%)
META   304.51 (+1.43%)
GOOGL   133.08 (+1.70%)
AMZN   128.93 (+1.42%)
TSLA   248.80 (-0.57%)
NVDA   444.74 (+2.24%)
NIO   8.77 (-2.99%)
BABA   86.16 (-0.67%)
AMD   102.24 (-0.56%)
T   14.75 (-1.80%)
F   12.27 (-1.21%)
MU   67.44 (-0.87%)
CGC   0.73 (-7.37%)
GE   108.65 (-1.72%)
DIS   81.41 (+0.44%)
AMC   8.05 (+0.75%)
PFE   33.76 (+1.78%)
PYPL   58.58 (+0.21%)
NFLX   380.13 (+0.67%)
NYSE:NVS

Novartis (NVS) Stock Forecast, Price & News

$101.52
-0.34 (-0.33%)
(As of 02:09 PM ET)
Compare
Today's Range
$100.96
$102.08
50-Day Range
$97.89
$104.90
52-Week Range
$74.24
$105.61
Volume
958,467 shs
Average Volume
1.83 million shs
Market Capitalization
$215.18 billion
P/E Ratio
28.28
Dividend Yield
2.24%
Price Target
$85.00

Novartis MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
15.8% Downside
$85.00 Price Target
Short Interest
Healthy
0.19% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.59mentions of Novartis in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.67%
From $6.92 to $7.52 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

656th out of 969 stocks

Pharmaceutical Preparations Industry

315th out of 453 stocks


NVS stock logo

About Novartis (NYSE:NVS) Stock

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

NVS Price History

NVS Stock News Headlines

Are Gene Therapy Stocks The Market's Next Big Winners? (NVS)
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
AI 2.0 is Here: How to Invest in a Generational Opportunity (NVS)
AI is sweeping the world but don't confuse apples with oranges; here's a look at the top 5 advancements in AI and who is using it.
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's Biosimilar
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Novartis (NYSE:NVS) Upgraded to Equal Weight at Morgan Stanley
Novartis' (NVS) Sandoz Gets Rights for Stelara Biosimilar
Novartis Recalls One Lot Of Sandimmune Oral Solution 100 Mg/mL
Novartis (NVS) Stock Moves -0.2%: What You Should Know
See More Headlines
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Company Calendar

Last Earnings
7/19/2023
Today
10/02/2023
Next Earnings (Confirmed)
10/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
101,703
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$85.00
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$85.00
Forecasted Upside/Downside
-16.3%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$6.96 billion
Pretax Margin
17.70%

Debt

Sales & Book Value

Annual Sales
$50.55 billion
Cash Flow
$6.28 per share
Book Value
$28.03 per share

Miscellaneous

Outstanding Shares
2,119,600,000
Free Float
2,119,388,000
Market Cap
$215.18 billion
Optionable
Optionable
Beta
0.53

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Vasant Narasimhan (Age 47)
    Chief Exec. Officer
    Comp: $5.76M
  • Mr. Harry Kirsch (Age 58)
    Chief Financial Officer
    Comp: $2.92M
  • Dr. Klaus Moosmayer Ph.D. (Age 55)
    Chief Ethics, Risk & Compliance Officer
    Comp: $1.59M
  • Ms. Karen L. Hale (Age 55)
    Chief Legal Officer
    Comp: $2.4M
  • Dr. Robert Kowalski Pharm.D. (Age 55)
    Chief People & Organization Officer
    Comp: $2.15M
  • Dr. Steffen Lang Ph.D. (Age 56)
    Pres of Operations
    Comp: $2.39M
  • Ms. Marie-France Tschudin (Age 52)
    Pres of Innovative Medicines International & Chief Commercial Officer
    Comp: $2.44M
  • Mr. Victor Bulto
    Pres of Innovative Medicines US
  • Dr. Shreeram Aradhye M.D. (Age 60)
    Pres of Global Drug Devel. & Chief Medical Officer
    Comp: $2.34M
  • Mr. Aharon Gal Ph.D.
    Chief Strategy & Growth Officer













NVS Stock - Frequently Asked Questions

Should I buy or sell Novartis stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View NVS analyst ratings
or view top-rated stocks.

What is Novartis' stock price forecast for 2023?

7 equities research analysts have issued 1-year target prices for Novartis' shares. Their NVS share price forecasts range from $85.00 to $85.00. On average, they predict the company's share price to reach $85.00 in the next year. This suggests that the stock has a possible downside of 16.3%.
View analysts price targets for NVS
or view top-rated stocks among Wall Street analysts.

How have NVS shares performed in 2023?

Novartis' stock was trading at $90.72 at the beginning of the year. Since then, NVS stock has increased by 11.9% and is now trading at $101.52.
View the best growth stocks for 2023 here
.

When is Novartis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 24th 2023.
View our NVS earnings forecast
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) posted its quarterly earnings results on Wednesday, July, 19th. The company reported $1.83 earnings per share for the quarter, topping analysts' consensus estimates of $1.68 by $0.15. The company earned $13.62 billion during the quarter, compared to analysts' expectations of $6.32 million. Novartis had a trailing twelve-month return on equity of 25.12% and a net margin of 14.76%. The business's revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.56 earnings per share.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis announced an annual dividend on Thursday, February 2nd. Shareholders of record on Friday, March 10th will be paid a dividend of $3.4694 per share on Monday, March 20th. This represents a dividend yield of 2.6%. The ex-dividend date is Thursday, March 9th. This is a boost from the stock's previous annual dividend of $1.18.
Read our dividend analysis for NVS
.

Is Novartis a good dividend stock?

Novartis (NYSE:NVS) pays an annual dividend of $2.27 per share and currently has a dividend yield of 2.23%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 63.23%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVS will have a dividend payout ratio of 30.19% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVS.

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $101.52.

How much money does Novartis make?

Novartis (NYSE:NVS) has a market capitalization of $215.18 billion and generates $50.55 billion in revenue each year. The company earns $6.96 billion in net income (profit) each year or $3.59 on an earnings per share basis.

How many employees does Novartis have?

The company employs 101,703 workers across the globe.

Does Novartis have any subsidiaries?
The following companies are subsidiares of Novartis: 1 A Pharma GmbH, Abadia Retuerta S.A, Admune Therapeutics, Advanced Accelerator Applications, Advanced Accelerator Applications, Advanced Accelerator Applications International SA, Advanced Accelerator Applications S.A., Advanced Accelerator Applications S.r.l., Advanced Accelerator Applications USA Inc., Aeropharm GmbH, Alcon, Alcon – Couvreur NV, Amblyotech, Amblyotech Inc., Arctos Medical, Arctos Medical AG, Australia Pty Ltd, Beijing Novartis Pharma Co. Ltd., BioMedical Research Co. Ltd., CELLforCURE, Cadent Therapeutics, Cadent Therapeutics Cambridge, Cellerys, Cellerys AG, CellforCure, Chiron Corporation, Ciba-Geigy Japan Limited, Co. Ltd, CoStim Pharmaceuticals, CoStim Pharmaceuticals Inc., Coalesce Product Development Limited, Corthera, Development Co. Ltd., EBEWE Pharma Ges.m.b.H Nfg. KG, Encore Vision, Endocyte, Endocyte Inc., Eon Labs Inc., Farmanova Saglik Hizmetleri Ltd, Fougera Pharmaceuticals, Fougera Pharmaceuticals Inc, Gyroscope Therapeutics, HEXAL AG, Hexal, IDB Holland BV, Iberica S.L.U., Ilaçlari Sanayi ve Ticaret A.S, JSC Sandoz, Japat AG, Kedalion Therapeutics Inc., Lek Pharmaceuticals d.d., Lek S.A., Manufacturing Pte Ltd , Navigate BioPharma Services Inc, Neutec Pharma Limited, Novartis (Hellas) S.A.C.I., Novartis (Singapore) Pte Ltd, Novartis (Taiwan) Co. Ltd, Novartis (Thailand) Limited, Novartis Argentina S.A., Novartis Australia Pty Ltd, Novartis Austria GmbH, Novartis Biociências S.A., Novartis Biosciences Perú S.A., Novartis Bioventures AG, Novartis Business Services GmbH, Novartis Capital Corporation, Novartis Chile S.A., Novartis Corporation, Novartis Corporation Sdn. Bhd., Novartis Deutschland GmbH, Novartis Ecuador S.A., Novartis Farma S.p.A., Novartis Farma – Produtos Farmacêuticos S.A., Novartis Farmacéutica S.A, Novartis Farmacéutica S.A. de C.V., Novartis Finance Corporation, Novartis Finance S.A., Novartis Finance Services Ltd, Novartis Finland Oy Espoo, Novartis Gene Therapies, Novartis Gene Therapies EU Limited, Novartis Gene Therapies Inc., Novartis Grimsby Limited, Novartis Groupe France S.A., Novartis Healthcare A/S, Novartis Healthcare Philippines Inc., Novartis Healthcare Private Limited, Novartis Holding AG, Novartis Hungary Healthcare Limited Liability Company, Novartis India Limited, Novartis Inflammasome Research, Novartis Integrated Services Limited, Novartis International AG, Novartis International Pharmaceutical Investment AG, Novartis Investment Ltd, Novartis Investments S.à r.l., Novartis Ireland Limited, Novartis Israel Ltd, Novartis Korea Ltd., Novartis Middle East FZE, Novartis Netherlands B.V., Novartis Neva LLC, Novartis New Zealand Ltd, Novartis Norge AS, Novartis Ophthalmics AG, Novartis Optogenetics Research Inc., Novartis Overseas Investments AG, Novartis Pharma (Logistics) Inc., Novartis Pharma (Pakistan) Limited, Novartis Pharma AG, Novartis Pharma B.V. , Novartis Pharma GmbH, Novartis Pharma GmbH, Novartis Pharma K.K., Novartis Pharma LLC, Novartis Pharma Maroc SA, Novartis Pharma NV, Novartis Pharma Produktions GmbH, Novartis Pharma S.A.E., Novartis Pharma S.A.S., Novartis Pharma Schweiz AG, Novartis Pharma Schweizerhalle AG, Novartis Pharma Services AG, Novartis Pharma Services Romania S.R.L., Novartis Pharma Stein AG, Novartis Pharmaceuticals Canada Inc., Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Limited, Novartis Pharmaceuticals UK Limited, Novartis Poland Sp. z o.o., Novartis Portugal S.G.P.S. Lda., Novartis Ringaskiddy Limited, Novartis Saglik Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S, Novartis Saudi Ltd., Novartis Securities Investment Ltd, Novartis Services Inc., Novartis Slovakia s.r.o., Novartis South Africa (Pty) Ltd, Novartis Sverige AB, Novartis UK Limited, Novartis US Foundation, Novartis Vaccines and Diagnostics Inc, Novartis Vietnam Company Limited, Novartis de Colombia S.A., Novartis de Venezuela S.A., Novartis s.r.o., Oriel Therapeutics Inc., PT. Novartis Indonesia, Protez Pharmaceuticals, Pte Ltd, Research Inc, Salutas Pharma GmbH, Sandoz A/S, Sandoz AG, Sandoz B.V., Sandoz Canada Inc., Sandoz Egypt Pharma S.A.E., Sandoz Farmacéutica S.A., Sandoz Farmacêutica Lda., Sandoz GmbH, Sandoz Hungary Limited Liability Company, Sandoz Ilaç Sanayi ve Ticaret A.S., Sandoz Inc, Sandoz Industrial Products S.A, Sandoz International GmbH, Sandoz K.K., Sandoz Limited, Sandoz Manufacturing Inc., Sandoz NV, Sandoz Pharma K.K, Sandoz Pharmaceuticals AG, Sandoz Pharmaceuticals d.d., Sandoz Philippines Corporation, Sandoz Polska Sp. z o.o. , Sandoz Private Limited, Sandoz Pty Ltd, Sandoz S.A. de C.V, Sandoz S.A.S., Sandoz S.R.L., Sandoz S.p.A., Sandoz South Africa (Pty) Ltd, Sandoz Ukraine LLC, Sandoz d.o.o. farmaceutska industrija, Sandoz do Brasil Indústria Farmacêutica Ltda, Sandoz s.r.o., Selexys Pharmaceuticals Corporation, Shanghai Novartis Trading Ltd., Société par actions SANDOZ, Spinifex Pharmaceuticals, The Medicines Company, The Medicines Company, Triangle International Reinsurance Limited, Trinity River Insurance Co Ltd, Vedere Bio, Vedere Bio ll, Xiidra, Ziarco, and Ziarco Group Limited.
Read More
How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The official website for the company is www.novartis.com. The company can be reached via phone at (161) 324-1111, via email at investor.relations@novartis.com, or via fax at 41-61-324-7826.

This page (NYSE:NVS) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -